| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453620 | Lung Cancer | 2018 | 27 Pages |
Abstract
Addition of fulvestrant to erlotinib was well tolerated, with increased activity noted among EGFR wild type patients compared to erlotinib alone, albeit in an unplanned subset analysis.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Edward B. Garon, Jill M. Siegfried, Laura P. Stabile, Patricia A. Young, Diana C. Marquez-Garban, David J. Park, Ravi Patel, Eddie H. Hu, Saeed Sadeghi, Rupesh J. Parikh, Karen L. Reckamp, Brad Adams, Robert M. Elashoff, David Elashoff, Tristan Grogan,